2025/01/01 by Tommaso Osti, Abdelrahman Taha, Eva Reviriego +5
Economics, Econometrics and Finance · Immunology and Microbiology · Medicine · #Biomedical Ethics and Regulation #Biosimilars and Bioanalytical Methods #Health Systems, Economic Evaluations, Quality of Life
paper · pdf · doi:10.1017/s0266462325103279
openalex publication_date 2025/01/01 · openalex created_date 2025/11/28 · openalex updated_date 2026/07/22
Abstract Background Despite omics technologies gaining traction in clinical settings, particularly in oncology, challenges persist in their widespread adoption due to the pre-requisite robust evidence supporting efficacy and cost-effectiveness. This study aims to explore the experiences of organizations working in the health technology assessment (HTA) field in evaluating omics technologies, with a particular focus on the adoption and application of specific assessment frameworks. Methods We conducted a global survey to gather insights into current practices and frameworks used in HTA evaluations of omics technologies. Results We gathered responses from thirty-nine participants representing organizations across twenty-nine countries and five continents. Among them, 51 percent (n = 20) reported experience in evaluating omics technologies, including multi-omics tests for early disease detection, biomarker-based cancer diagnostics, and advanced genomic sequencing techniques. Only three organizations employed specific assessment frameworks: the Adelaide Health Technology Assessment Agency in Australia, the Netherlands Cancer Institute , and the Andalusian HTA Agency in Spain. These frameworks address key evaluation aspects such as analytical and clinical validity, clinical and personal utility, organizational impact, and ethical, legal, and social implications of omics technologies. Discussion Despite their relevance, the limited adoption of tailored frameworks highlights the need for more structured and context-specific approaches to facilitate the integration of omics technologies into healthcare systems. Collaborative efforts among stakeholders, including patients, healthcare providers, policymakers, and industry representatives, are crucial for devising robust evaluation strategies addressing the complexities of omics technologies comprehensively.